Drugs.com - New Drug Approvals

U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors

WHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Vitrakvi® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and...

May 12, 2025 - 10:14
 0
WHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Vitrakvi® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and...
Read More

Tags:

Previous Article

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefilled Syringe for Self-Inje...

Next Article

FDA Approves an Updated Label for Tryvio (aprocitentan) Removing the REMS Requir...

Related Posts

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefil...

May 12, 2025  0

Alnylam Announces FDA Approval of Amvuttra (vutrisiran)...

May 12, 2025  0

FDA Approves Yutrepia (treprostinil) Inhalation Powder for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

FDA Approves Yutrepia (treprostinil) Inhalation Powder ...

May 27, 2025  0